The subsequent clinical improvement following IVIG underscores the importance of combined immunomodulation—particularly in PD-1 inhibitor–associated TEN, where multisystem immune dysregulation often necessitates a multi-targeted approach. Here, PDCD1 is linked to toxic epidermal necrolysis.